Breaking News

Kemwell Completes Successful FDA Inspection

February 1, 2013

PAI triggered by a top pharma company’s NDA filing

Kemwell Biopharma’s oral solids manufacturing facility in Bangalore, India has successfully completed a U.S. FDA inspection. The cGMP Audit for a Pre-Approval Inspection (PAI) was triggered by a NDA filing by a top ten global pharmaceutical company.  
 
Kemwell's R&D and manufacturing teams, along with the customer, optimized tablet formulation, conducted process scale-up studies, and manufactured the validation and submission batches for this NDA filing. The audit involved a review and evaluation of all systems, procedures and processes related to the development, validation and manufacture of oral solids at the site.
 
"The approval from the US FDA confirms Kemwell's cGMP manufacturing capability and regulatory compliance, and our commitment to provide our customers the highest standards of quality. The facility has been approved by many global regulatory authorities, including EMA, MHRA, Health Canada and TGA. We will continue to strive to provide excellent quality pharmaceutical products and deliver on the highest customer service expectations," said Anurag Bagaria, chairman and managing director.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important